Skip to content

Effects of dexmedetomidine combined with epidural anesthesia on intestinal function and postoperative outcomes of patients undergoing laparoscopic colorectal cancer surgery

Effects of dexmedetomidine combined with epidural anesthesia on intestinal function and postoperative outcomes of patients undergoing laparoscopic colorectal cancer surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063569
Enrollment
Unknown
Registered
2022-09-12
Start date
2022-10-01
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Control group (CON group):Intravenous and inhalation combined anesthesia, equal amount of normal saline
Sufentanil PCIA.
Dexmedetomidine group (DEX group):Dexmedetomidine group (DEX group): intravenous anesthesia was assisted by intravenous of DEX with the loading dose of 0.5~1.0 microgram/kg completed within 10 minutes
Epidural group (EP group):Intravenous Inhalation Combined with epidural anesthesia, ropivacaine + sufentanil PCEA
DEX + EP group:Intravenous anesthesia assisted by intravenous DEX combined with epidural anesthesia, ropivacaine + DEX PCEA.

Sponsors

Shaoxing people's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Male or female patients aged between 18 and 75; 2) Body mass index (BMI) is between 18 and 30; 3) Laparoscopic radical resection of colorectal cancer under ASA I-II general anesthesia; 4) Agreed to participate in the experiment and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1) Heart rate is lower than 55 beats/ min or stage III hypertension; 2) Diabetes or difficult airway; 3) Patients with heart, liver, kidney or immune system diseases; 4) Patients with neurological disease, language disorder and hearing impairment who cannot communicate and cooperate. 5) Patients with systemic infection (body temperature higher than 38 ?), blood system disease, coagulation dysfunction, infection at epidural puncture site, anticoagulant treatment, etc. who do not meet the requirements of epidural puncture; 6) Patients with allergic constitution; 7) Pregnant women or breast-feeding patients.

Design outcomes

Primary

MeasureTime frame
Peristalsis time after operation;Oral feeding time after operation;

Secondary

MeasureTime frame
D-lactic acid;FABP2;SCD1;DAO;LPS;MDA;TNF-a;IL-6;Immune indicators: T cells (CD3), helper/induced T cells (CD4), inhibitory / cytotoxic T cells (CD8), NK cells, total B cells (CD19) and CD4/CD8 ratio;Arterial blood environmental indicators: arterial blood gas, electrolyte and acid-base balance;;Hemodynamic indexes: BP, CVP;Intraoperative fluid volume;Dose of narcotic drugs;;Blood biochemical indexes before and 1 day after operation;;According to the international surgical outcomes study (ISOs) standard, the in-hospital complications and mortality of patients 30 days after surgery were investigated;Investigation of postoperative analgesia effect;

Countries

China

Contacts

Public ContactRui He
15347172@qq.com13575546562

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026